Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
STAT11h
Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug
Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
Understanding the link between hormones and women’s weight
Whether it’s conditions like premenstrual dysphoric disorder (PMDD) being discussed on primetime TV shows or workplaces ...
Men face higher cancer risk with this specific body fat measurement
New research suggests that a larger waist circumference is a bigger risk factor than body mass index (BMI) for ...
Novo bets on Triple G obesity drug in up to $2 bn deal with Chinese biotech
Novo has been trying to strengthen its foothold in the potential $150 billion obesity market through the development of ...
Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women
Body size and excess weight, conventionally assessed using body mass index (BMI), are well-established risk factors for many ...
Rolling Out4d
How your body clock controls your hormones and health
Your body clock regulates hormones that impact mood, metabolism, and sleep. Learn how to align your lifestyle with your ...
Health on MSN4d
Menopause Diet: Foods and Drinks to Balance Hormones and Replenish Nutrients
Medically reviewed by Suzanne Fisher, RD Menopause is a natural phase in life that signifies the end of menstruation, ...
Novo Licenses Chinese Biotech's Obesity Drug Candidate for up to $2 Billion
(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United ...
Wall Street Journal1d
Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug
said it signed an exclusive global licensing deal for UBT251, a drug that targets three different hormones to treat obesity, type 2 diabetes, and other diseases.